API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/08/2859131/0/en/Corcept-Completes-Enrollment-in-Pivotal-Phase-3-Rosella-Trial-of-Relacorilant-in-Patients-With-Platinum-Resistant-Ovarian-Cancer.html
https://www.globenewswire.com/news-release/2024/04/01/2855141/0/en/Corcept-Completes-Enrollment-in-Phase-3-Gradient-Trial-of-Relacorilant-in-Patients-With-Adrenal-Cushing-s-Syndrome.html
https://www.globenewswire.com/news-release/2022/06/06/2456669/0/en/Corcept-Therapeutics-to-Start-Phase-3-Trial-of-Relacorilant-Plus-Nab-Paclitaxel-in-Patients-With-Platinum-Resistant-Ovarian-Cancer.html
https://www.globenewswire.com/news-release/2022/03/30/2413251/0/en/Relacorilant-Plus-Nab-Paclitaxel-Extends-Survival-in-Women-with-Recurrent-Platinum-resistant-Ovarian-Cancer.html
https://www.globenewswire.com/news-release/2021/09/17/2299097/0/en/Positive-Results-Presented-at-ESMO-2021-From-Randomized-Controlled-Phase-2-Trial-of-Relacorilant-in-Patients-with-Recurrent-Platinum-Resistant-Ovarian-Cancer.html
https://www.globenewswire.com/news-release/2021/09/09/2294773/0/en/Corcept-Announces-Presentation-of-Positive-Results-From-Randomized-Controlled-Phase-2-Trial-of-Relacorilant-in-Patients-With-Recurrent-Platinum-Resistant-Ovarian-Cancer-at-ESMO-202.html
https://www.globenewswire.com/news-release/2020/06/30/2055804/0/en/Corcept-Therapeutics-Initiates-Phase-3-Trial-of-Relacorilant-Plus-Nab-Paclitaxel-in-Patients-with-Metastatic-Pancreatic-Cancer.html
https://globenewswire.com/news-release/2018/06/04/1515989/0/en/Corcept-Therapeutics-Announces-Positive-Relacorilant-Data-at-the-2018-American-Society-of-Clinical-Oncology-Meeting.html